COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback